NasdaqCM:NKTRPharmaceuticals
How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials
Nektar Therapeutics recently initiated the first two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, for rezpegaldesleukin in patients aged 12 and older with moderate-to-severe atopic dermatitis, following encouraging Phase 2b data and prior FDA Fast Track designations.
This move advances a first-in-class T-reg–targeting biologic into pivotal testing across North America, Europe and Asia-Pacific, underscoring Nektar’s ambition to build a broad autoimmune and inflammatory...